

VIP Very Important Paper

Protein-Protein Recognition Involved in the Intermodular Transacylation Reaction in Modular Polyketide Synthase in the Biosynthesis of Vicenistatin

Taichi Chisuga,^[a] Akimasa Miyana^ga,*^[a] and Tadashi Eguchi*^[a]

The ketosynthase (KS) domain is a core domain found in modular polyketide synthases (PKSs). To maintain the polyketide biosynthetic fidelity, the KS domain must only accept an acyl group from the acyl carrier protein (ACP) domain of the immediate upstream module even when they are separated into different polypeptides. Although it was reported that both the docking domain-based interactions and KS-ACP compatibility are important for the interpolypeptide transacylation reaction in 6-deoxyerythronolide B synthase, it is not clear

whether these findings are broadly applied to other modular PKSs. Herein, we describe the importance of protein-protein recognition in the intermodular transacylation between VinP1 module 3 and VinP2 module 4 in vicenistatin biosynthesis. We compared the transacylation activity and crosslinking efficiency of VinP2 KS₄ against the cognate VinP1 ACP₃ with the non-cognate one. As a result, it appeared that VinP2 KS₄ distinguishes the cognate ACP₃ from other ACPs.

Introduction

Polyketide synthases (PKSs) are responsible for the biosynthesis of various structurally diverse bioactive polyketide natural products.^[1] Bacterial modular type I PKSs are huge multifunctional proteins, and are comprised of multiple modules, each of which contains a set of catalytic domains for one round of polyketide chain elongation.^[2] Ketosynthase (KS), acyltransferase (AT), and acyl carrier protein (ACP) domains are essential for the polyketide chain elongation in each module. In the polyketide chain elongation in the Nth module, the AT domain (AT_N) transfers a specific malonyl-type extender unit onto the terminal thiol group of the phosphopantetheine arm of the ACP_N. KS_N receives the growing polyketide chain on the thiol group of the catalytic Cys residue from the ACP domain (ACP_{N-1}) of the upstream N-1th module, and subsequently catalyzes a decarboxylative Claisen-like condensation with the malonyl-type extender unit on ACP_N to afford β-ketoacyl-ACP_N (Figure 1). This β-ketoacyl-group is optionally modified by reduction and dehydration reactions catalyzed by other catalytic domains thus completing the polyketide chain elongation in the Nth module. The acyl group on ACP_N is transferred to KS_{N+1}, which initiates the polyketide chain elongation in the N+1th module. To maintain the structural integrity of the polyketide products, the




Figure 1. Proposed reaction mechanism of the type I PKS KS domain.

growing polyketide chain must be transferred between modules in the correct order.

For the functional intermodular transacylation reaction of the KS_N domain, KS_N must only accept an acyl group from the ACP_{N-1} domain of the immediate upstream module. When KS_N and ACP_{N-1} are separated into different polypeptides, complementary short linker regions referred to as docking domains (DDs) located at the N-terminus of KS_N and C-terminus of ACP_{N-1} (called NDD_N and CDD_{N-1}, respectively) have been shown to mediate the functional intermodular transacylation reaction between polypeptides.^[3] Several studies show that docking domain compatibility is essential to maintain the biosynthetic fidelity in the intermodular transacylation reaction between polypeptides in bacterial *cis*-AT PKSs.^[4–7] The protein-protein recognition between KS_N and ACP_{N-1} was also reported to be important in the intermodular transacylation reaction between polypeptides in 6-deoxyerythronolide B synthase (DEBS).^[8,9] However, studies on the KS_N-ACP_{N-1} interactions between

[a] T. Chisuga, Dr. A. Miyana^ga, Prof. Dr. T. Eguchi
Department of Chemistry
Tokyo Institute of Technology, 2-12-1 O-okayama
Meguro-ku, Tokyo 152-8551 (Japan)
E-mail: miyana^ga.aa@m.titech.ac.jp
eguchi@chem.titech.ac.jp

Supporting information for this article is available on the WWW under <https://doi.org/10.1002/cbic.202200200>

© 2022 The Authors. ChemBioChem published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

polypeptides have been limited to DEBS among the bacterial *cis*-AT PKSs. Therefore, it is necessary to investigate whether the findings on selective KS_N - ACP_{N-1} interactions are broadly applicable to other modular type I *cis*-AT PKSs to better understand the molecular basis of intermodular transacylation reactions in modular type I *cis*-AT PKSs.

In this study, we performed *in vitro* analysis of the intermodular transacylation reaction between VinP1 module 3 (UniProt; Q76KY0) and VinP2 module 4 (UniProt; Q76KZ5) from the macrolactam antibiotic vicenistatin PKS^[10] to gain insights into protein-protein recognition in the intermodular transacylation reaction between the polypeptides.

Results and Discussion

The intermodular transacylation reaction between VinP1 module 3 and VinP2 module 4

To determine the importance of protein-protein recognition in the intermodular transacylation reaction in which the modules are separated into different polypeptides, we attempted to analyze the transacylation reaction from acyl- ACP_{N-1} - CDD_{N-1} to NDD_N - KS_N . We selected the VinP2 KS_4 domain ($_4$; in module 4) (Pro35-Pro461), which is predicted to accept a polyketide intermediate from the upstream module 3 in vicenistatin biosynthesis (Figure 2A).^[10] Module 3 and module 4 of vicenistatin PKS are separated into VinP1 and VinP2, respectively, and the docking domains are located at the C-terminus of VinP1 (CDD_3 ; Asp5813-Leu5823) and at the N-terminus of VinP2 (NDD_4 ; Met1-Glu34) (Figure S1). VinP1 CDD_3 and VinP2 NDD_4 belong to class 1 docking domains^[3] and have high amino acid sequence similarities with the structurally characterized DEBS2 CDD_4 and DEBS3 NDD_5 at 55% and 50%, respectively (Figure S2). We expected that *in vitro* analysis of the transacylation reaction of the VinP2 KS_4 domain is suitable for evaluation of the protein-protein recognition involved in the intermodular transacylation reaction between polypeptides. We expressed recombinant VinP2 NDD_4 - KS_4 protein that contained the neighboring AT_4 domain (Met1-Gly931) in *Escherichia coli* because it was reported that type I PKS KS recombinant protein expressed as a single domain is often obtained as an insoluble form.^[11,12] To exclude the effect of the VinP2 AT_4 domain, we prepared the VinP2 NDD_4 - KS_4 - AT_4 S684G mutant in which the catalytic Ser684 residue of the AT_4 domain was mutated. We also expressed recombinant VinP1 ACP_3 - CDD_3 protein (Asp5651-Asp5826) (Figure S3) in *E. coli*. We prepared tiglyl- and butyryl-VinP1 ACP_3 - CDD_3 (Figures 2B, S4A) as simplified mimics of the native substrate for the VinP2 KS_4 domain (Figure 2A) by the enzymatic reaction of phosphopantetheinyl transferase Sfp^[13] with VinP1 ACP_3 - CDD_3 in the presence of tiglyl-CoA and butyryl-CoA, respectively (Figure S5).

We performed the transacylation reaction of VinP2 NDD_4 - KS_4 by mixing 50 μ M of VinP2 NDD_4 - KS_4 - AT_4 S684G and 50 μ M of tiglyl- or butyryl-VinP1 ACP_3 - CDD_3 , and analyzed the reaction products by high-performance liquid chromatography (HPLC). As a result, both tiglyl- and butyryl-VinP1 ACP_3 - CDD_3 were




Figure 2. Transacylation reaction between the VinP2 NDD_4 - KS_4 domain and VinP1 ACP_3 - CDD_3 . A) The substrate of the VinP2 KS_4 domain. B) Tiglyl- ACP_3 - CDD_3 , which is a substrate mimic for the VinP2 KS_4 domain. C) The transacylation reaction between tiglyl-VinP1 ACP_3 - CDD_3 and VinP2 NDD_4 - KS_4 - AT_4 S684G. D) HPLC analysis of the transacylation reaction between the VinP2 NDD_4 - KS_4 domain and VinP1 ACP_3 - CDD_3 .

consumed, and holo-VinP1 ACP_3 - CDD_3 was produced by the transacylation reaction (Figure 2C, D, Figures S4B, S6A). By comparison, in the reaction with VinP2 NDD_4 - KS_4 - AT_4 C206G/S684G in which the catalytic Cys206 of the KS_4 domain was mutated (Figure S7A), the consumption of tiglyl- and butyryl-VinP1 ACP_3 - CDD_3 was almost undetectable (Figures 2D, S4B). These results showed that the transacylation reaction from VinP1 ACP_3 - CDD_3 to VinP2 NDD_4 - KS_4 occurs on the catalytic Cys206 of the KS_4 domain. VinP2 NDD_4 - KS_4 showed similar activities against tiglyl- and butyryl-VinP1 ACP_3 - CDD_3 (Table S1), suggesting that the VinP2 KS_4 domain is tolerant to hydrophobic acyl groups at the α and β positions. We selected tiglyl-VinP1 ACP_3 - CDD_3 for further analysis because the tiglyl group is more similar to the native polyketide intermediate for the transacylation reaction of the VinP2 KS_4 domain.

The KS domains of PKSs have two conserved His residues located near the catalytic Cys residue (Figure S7A, B). Using the in vitro analytical system of the VinP2 NDD₄KS₄ domain, we performed mutational analysis of the two conserved His residues (His341 and His381) of the VinP2 KS₄ domain. As a result, VinP2 KS₄AT₄ H341A/S684G and H381A/S684G showed significantly reduced transacylation activity (Figures S7A, S8, Table S2), which is consistent with previous mutational analysis of the DEBS1 KS₁ domain.^[14] These results suggest that the two conserved His residues are important for the transacylation reaction (Figure S9).

The protein-protein recognition between VinP2 NDD₄KS₄ and ACPCDD in the transacylation reaction

In vicenistatin biosynthesis, VinP2 ACP₄CDD₄ and VinP3 ACP₆CDD₆ are also involved in the intermodular transacylation reaction between polypeptides in addition to VinP1 ACP₃CDD₃ (Figure S1). VinP2 NDD₄KS₄ must only accept an acyl substrate from VinP1 ACP₃CDD₃ to maintain the biosynthetic fidelity. To confirm that VinP2 NDD₄KS₄ can distinguish VinP1 ACP₃CDD₃ from other ACPCDDs, we carried out the transacylation reaction using tiglyl-VinP2 ACP₄CDD₄ and tiglyl-VinP3 ACP₆CDD₆, respectively (Figures S10, S11). As expected, the formation of holo-VinP2 ACP₄CDD₄ and holo-VinP3 ACP₆CDD₆ was not detected (Table 1, Figure S12), implying that VinP2 NDD₄KS₄ does not accept an acyl group from VinP2 ACP₄CDD₄ or VinP3 ACP₆CDD₆. Thus, the exchange of ACPCDD resulted in a significant decrease in the transacylation activity of VinP2 NDD₄KS₄ (Table 1), confirming that the protein-protein recognition between ACP₃CDD₃ and NDD₄KS₄ is important for the intermodular transacylation reaction between VinP1 and VinP2.

Next, we assessed the importance of the ACP and CDD parts for the transacylation reaction of VinP2 NDD₄KS₄. First, we evaluated the effect of the CDD part on the transacylation reaction of VinP2 NDD₄KS₄. VinP1 ACP₃CDD₃ has a post-ACP dimerization element (DE) region, which promotes dimerization of an ACPCDD protein, between the ACP domain and CDD as reported for other class 1 DDs (Figure S3A, B).^[6] To assess the effect of the CDD part only, we prepared VinP1 ACP₃DE₃ (Asp5651-Gln5798), from which CDD₃ (Asp5813-Asp5826) was removed, and then performed the transacylation reaction of

VinP2 NDD₄KS₄ with tiglyl-VinP1 ACP₃DE₃ (Figure S13). As a result, VinP2 NDD₄KS₄ showed a significantly reduced activity against tiglyl-VinP1 ACP₃DE₃ (Table 1, Figure S14), indicating that the CDD₃ part is very important for protein-protein recognition in the transacylation reaction of VinP2 NDD₄KS₄. The interactions between VinP1 CDD₃ and VinP2 NDD₄ are presumed to be formed by the interaction of the hydrophobic surface and two salt bridges as observed for DEBS2 CDD₄ and DEBS3 NDD₅, between which the detailed interface interaction was previously elucidated by NMR spectroscopy analysis^[6] (Figure S2C).

To evaluate the importance of the ACP part for the protein-protein recognition in the transacylation reaction of VinP2 NDD₄KS₄, we designed chimeric ACP_xCDD₃ proteins (x; module number) in which the ACP₃ part of VinP1 ACP₃CDD₃ was replaced with other ACP domains. We fused the ACP domain of another module with the N-terminus of the VinP1 DE₃CDD₃ part (Glu5747-Asp5826) to generate the chimeric ACP_xCDD₃ proteins ACP₄CDD₃, ACP₆CDD₃ and ACP₇CDD₃ (Figures S15–S19). We then performed the transacylation reaction of VinP2 NDD₄KS₄ with the tiglyl-chimeric ACP_xCDD₃ protein (Figures S20–S22). The results showed that the activities against all chimeric ACP_xCDD₃ proteins were greatly reduced compared to that against cognate VinP1 ACP₃CDD₃ (Table 1, Figure S23). Interestingly, VinP2 NDD₄KS₄ showed relatively high activity against tiglyl-ACP₄CDD₃, among the tiglyl-chimeric ACP_xCDD₃ proteins. Previous studies of the type I PKS KS domain suggested that the binding mode of the upstream module ACP_{N-1} to the KS_N domain is different from that of the same module ACP_N.^[15,16] The VinP2 ACP₄ domain interacts with the VinP2 KS₄ domain to provide a methylmalonyl extender unit during the Claisen-like condensation reaction. Therefore, the VinP2 KS₄ domain might be able to interact with the tiglyl-VinP2 ACP₄ domain in a binding mode suitable for condensation although the binding mode of the VinP1 ACP₄ domain is less favorable for the transacylation reaction than that of the VinP1 ACP₃ domain. Comparison of the transacylation activities against these chimeric ACP_xCDD₃ proteins revealed that the ACP moiety is also important for the transacylation reaction of VinP2 NDD₄KS₄.

Evaluation of the protein-protein recognition between VinP2 NDD₄KS₄ and ACPCDDs by the crosslinking reaction

Comparison of the transacylation activities showed that the protein-protein recognition of both the VinP1 ACP₃-VinP2 KS₄ domain and VinP1 CDD₃-VinP2 NDD₄ are important for the intermodular transacylation reaction between the VinP1 module 3 and VinP2 module 4. To further evaluate the protein-protein recognition between the VinP2 NDD₄KS₄ and ACPCDD proteins, we performed another assay using crosslinking probes. Recently, many crosslinking probes have been used as chemical tools to enable structural and functional characterization of the transient interactions between the catalytic domains and ACP domains in PKS and fatty acid synthase.^[17–23] Therefore, we investigated the efficiencies of crosslinking between the VinP2 NDD₄KS₄ and ACPCDD proteins to compare with the results of

Table 1. Initial velocity of the transacylation reaction between the VinP2 NDD₄KS₄ domain and the tiglyl-ACPCDD proteins.

ACP part	CDD part	Initial velocity [nM/min] ^[a]
ACP3	CDD3	436 ± 34
ACP3	none	trace ^[b]
ACP4	CDD4	trace
ACP6	CDD6	trace
ACP4	CDD3	76.2 ± 5.0
ACP6	CDD3	10.5 ± 2.2
ACP7	CDD3	15.7 ± 1.3

[a] Initial velocity of 50 μM VinP2 NDD₄KS₄AT₄ S684G and 50 μM tiglyl-ACPCDD. [b] Initial velocity < 10 nM/min.

the analysis of the transacylation reaction. To crosslink the VinP2 NDD₄KS₄ and ACP₃CDD₃ proteins, we used Br-acetyl pantetheinamide and Cl-acetyl pantetheinamide, both of which are phosphopantetheine analogs that have electrophilic reactive groups at their terminus.^[20,24–26] We prepared *crypto*-VinP1 ACP₃CDD₃, which is VinP1 ACP₃CDD₃ modified with α -haloacylpantetheinamides using CoA biosynthetic enzymes (CoaA, CoaD and CoaE) and Sfp (Figure S5).^[27] The thiol group of the Cys206 catalytic residue of the VinP2 KS₄ domain was expected to participate in a nucleophilic attack on the α -haloacylpantetheinamide moiety on the *crypto*-ACP₃CDD₃ protein to form a covalent bond (Figure 3A). We performed the crosslinking reaction by mixing 200 μ M *crypto*-VinP1 ACP₃CDD₃ and 50 μ M VinP2 NDD₄KS₄AT₄ S684G, and then analyzed the crosslinking efficiency by SDS-PAGE (Figures 3B, S24). The crosslinking reaction using Br-acetyl pantetheinamide-VinP1 ACP₃CDD₃ gave several crosslinked complexes, while the crosslinking reaction using Cl-acetyl pantetheinamide-VinP1 ACP₃CDD₃ gave a single crosslinked complex (Figures 3B, S24). In the case of VinP2 NDD₄KS₄AT₄ C206G/S684G, the reaction with Br-acetyl pantetheinamide-VinP1 ACP₃CDD₃ resulted in the formation of the crosslinked complex. These observations suggest that the Br-acetoamide group is too reactive toward VinP2 NDD₄KS₄AT₄, resulting in the formation of undesired crosslinked complexes via other nucleophilic residues as reported for the VinK-VinL crosslinking reaction.^[28] By comparison, in the crosslinking reaction of VinP2 NDD₄KS₄AT₄ C206G/S684G using Cl-acetyl pantetheinamide-VinP1 ACP₃CDD₃, almost no crosslinked complex was generated. Thus, Cl-acetyl pantetheinamide-VinP1 ACP₃CDD₃ only reacts with the Cys206 catalytic residue, and

seems to be suitable for the crosslinking reaction between VinP2 NDD₄KS₄ and VinP1 ACP₃CDD₃.

Next, we compared the efficiency of the crosslinking reaction of the VinP2 KS₄ domain with cognate ACP₃ and noncognate ACP proteins. Cl-Acetyl pantetheinamide was used to prepare each *crypto*-ACP protein in the same manner as *crypto*-VinP1 ACP₃CDD₃. We mixed 50 μ M VinP2 NDD₄KS₄AT₄ S684G with 200 μ M *crypto*-ACP protein, and quantified the amount of crosslinked complexes using SDS-PAGE (Figure 3C, Table S3). The amount of the crosslinked complex with ACP₃DE₃ was much lower than that with VinP1 ACP₃CDD₃, confirming the importance of the docking domain in the crosslinking reaction between the VinP2 KS₄ domain and ACP₃DE₃ (Table S3). The crosslinking reaction with ACP₄CDD₄ and ACP₆CDD₆ gave almost no crosslinked complex. The crosslinking reaction using chimeric ACP_xCDD₃ proteins also resulted in a substantial decrease in the amount of the crosslinked complex, except for a modest decrease in the case of ACP₄CDD₃. These crosslinking reaction results are consistent with those of the transacylation reaction (Table 1, S3).

Conclusion

In this study, we investigated the protein-protein recognition involved in the intermolecular transacylation reaction between VinP1 ACP₃CDD₃ and VinP2 NDD₄KS₄ in vicenistatin PKS. It was found that both the VinP1 CDD₃ and ACP₃ parts are important for the transacylation activity of VinP2 NDD₄KS₄. Furthermore, the substitution of the VinP1 ACP₃ part with other ACP domains




Figure 3. A) Crosslinking between VinP2 NDD₄KS₄AT₄ S684G and *crypto*-VinP1 ACP₃CDD₃. B) SDS-PAGE analysis of the crosslinking reaction with Cl-acetyl pantetheinamide-ACP₃CDD₃. Lane M: Protein Marker. Lanes 1–4: crosslinking reaction of VinP2 NDD₄KS₄AT₄ S684G at 0, 15, 120 and 360 min reaction times, respectively. Lanes 5–8: crosslinking reaction of VinP2 NDD₄KS₄AT₄ C206G/S684G at 0, 15, 120 and 360 min reaction times, respectively. C) Crosslinking reaction of VinP2 NDD₄KS₄AT₄ S684G with various *crypto*-ACP proteins. Lane M: Protein Marker. Lane 1: without *crypto*-ACP. Lane 2: with *crypto*-ACP₃CDD₃. Lane 3: with *crypto*-ACP₄CDD₄. Lane 4: with *crypto*-ACP₆CDD₆. Lane 5: with *crypto*-ACP₃CDD₃. Lane 6: with *crypto*-ACP₄CDD₃. Lane 7: with *crypto*-ACP₆CDD₃. Lane 8: with *crypto*-ACP₃CDD₃.

resulted in significantly reduced crosslinking efficiency between ACP₃CDD₃ and VinP2 NDD₄KS₄. These results suggest the importance of the protein-protein recognition between VinP2 NDD₄KS₄ and VinP1 ACP₃CDD₃ in the intermodular transacylation reaction. The protein-protein recognition mechanism between the NDD and CDD of *cis*-AT PKSs involved in the intermodular transacylation reactions between polypeptides has been elucidated in detail based on structural analysis.^[6,7,29] However, the protein-protein recognition mechanism between the KS domain and the upstream ACP of type I PKSs is not fully understood although the results from various *in vitro* experiments and low-resolution cryo-electron microscopy analysis have successfully identified the regions of ACP involved in the protein-protein recognition between the KS domain and the upstream ACP.^[8,9,15,30,31] A high-resolution structure of a type I PKS KS domain complexed with the upstream ACP is necessary to fully understand the protein-protein recognition mechanism between the KS domain and the upstream ACP in the intermodular transacylation reaction.

Experimental Section

Preparation of the VinP2 NDD₄KS₄AT₄ protein, VinP1 ACP₃CDD₃, VinP1 ACP₃ domain and chimeric ACP_xCDD₃ proteins: The *vinP2* NDD₄KS₄AT₄ fragment was amplified by PCR using cosmid K1B10^[10] as the template DNA with the oligonucleotides shown in Table S4. The amplified fragment was cloned into the expression vector pET30 (Novagen) using *Nde*I and *Eco*RI restriction sites to form pET30-*vinP2* NDD₄KS₄AT₄. For preparation of pET30-*vinP2* NDD₄KS₄AT₄ S684G, site-directed mutagenesis was performed using pET30-*vinP2* NDD₄KS₄AT₄ as the template DNA with the oligonucleotides shown in Table S4. For preparation of pET30-*vinP2* NDD₄KS₄AT₄ C206G/S684G, site-directed mutagenesis was performed using pET30-*vinP2* NDD₄KS₄AT₄ S684G as the template DNA with the oligonucleotides shown in Table S4. These plasmids were transformed into *E. coli* RosettaTM 2(DE3) (Novagen).

For the expression of the VinP2 NDD₄KS₄AT₄ protein, *E. coli* RosettaTM 2(DE3) cells harboring pET30-*vinP2* NDD₄KS₄AT₄ were grown at 37 °C in Luria-Bertani (LB) broth containing kanamycin (50 µg/mL) and chloramphenicol (20 µg/mL). When the optical density at 600 nm reached 0.6, protein expression was induced by the addition of 0.2 mM isopropyl β-D-1-thiogalactopyranoside (IPTG), and the cells were then cultured for an additional 20 h at 15 °C. The harvested cell pellets were suspended in buffer A [50 mM HEPES–Na (pH 8.0), 100 mM NaCl, and 10% (w/v) glycerol] and lysed by sonication. The recombinant VinP2 NDD₄KS₄AT₄ protein was purified from the lysate using a His60 Ni Superflow affinity column (Clontech). The protein solution was then desalted and concentrated using a PD-10 column (Cytiva) and an Amicon Ultra 10 K centrifugal filter (Merck Millipore). The VinP2 NDD₄KS₄AT₄ S684G mutant and C206G/S684G double mutant were also prepared as described above.

The *vinP1* ACP₃CDD₃ fragment was amplified by PCR using cosmid K1B10 as the template DNA with the oligonucleotides shown in Table S5. The amplified fragment was cloned into the expression vector pColdW (modified vector derived from pColdI)^[12] using *Nde*I and *Xho*I restriction sites to form pColdW-*vinP1* ACP₃CDD₃. For the expression of the VinP1 ACP₃CDD₃, *E. coli* BL21(DE3) (Nippon Gene Co., Ltd.) cells harboring pColdW-*vinP1* ACP₃CDD₃ were grown at 37 °C in LB broth containing ampicillin (50 µg/mL). When the optical density at 600 nm reached 0.4, protein expression was induced by

the addition of 0.2 mM IPTG, and the cells were then cultured for an additional 20 h at 15 °C. The harvested cell pellets were suspended in buffer A and lysed by sonication. The recombinant VinP1 ACP₃CDD₃ protein was purified from the lysate in the same manner as the VinP2 NDD₄KS₄AT₄ protein. The *vinP1* ACP₃DE₃ fragment was amplified by PCR using pColdW-*vinP1* ACP₃CDD₃ as the template DNA with the oligonucleotides shown in Table S5. The amplified fragment was cloned into the expression vector pColdW using *Nde*I and *Xho*I restriction sites to form pColdW-*vinP1* ACP₃DE₃. Expression and purification of VinP1 ACP₃DE₃ were carried out using the same procedures as those for VinP1 ACP₃CDD₃.

The detailed methods for the construction of the plasmids encoding the chimeric ACP_xCDD₃ protein are described in the Supporting Information. Expression and purification of the chimeric ACP_xCDD₃ proteins were performed in the same manner as for VinP1 ACP₃CDD₃.

Preparation of holo- and acyl-ACP proteins: Tiglyl-VinP1 ACP₃CDD₃ was prepared by an enzymatic reaction using the phosphopantetheinyl transferase Sfp.^[13] A total of 200 µM apo-VinP1 ACP₃CDD₃ in buffer A was mixed with 20 µM Sfp, 2 mM tiglyl-CoA and 5 mM MgCl₂, and then incubated at 28 °C for 10 min. After the reaction, the solution was directly used for the transacylation reaction assay. Preparation of holo- and butyryl-VinP1 ACP₃CDD₃ was performed in the same manner except for exchange of tiglyl-CoA with CoA and butyryl-CoA, respectively. Other holo- and tiglyl-ACP_xCDD_x proteins were prepared using the same procedure as holo- and tiglyl-VinP1 ACP₃CDD₃.

Analysis of the transacylation reaction between the VinP2 NDD₄KS₄ and acyl-ACPCDD proteins: For analysis of the transacylation reaction between VinP2 NDD₄KS₄ and tiglyl-VinP1 ACP₃CDD₃, 50 µM VinP2 NDD₄KS₄ S684G was mixed with 50 µM tiglyl-VinP1 ACP₃CDD₃ in buffer A. The reaction mixture was incubated at 28 °C for 8, 15, 30, 60, 120 and 240 min, and an equal volume of acetonitrile was then added to the solution. The mixtures were subjected to HPLC analysis using a Hitachi instrument (Chromaster Pump 5110, Diode Array Detector 5430, and Column Oven 5310) equipped with a Protein-R column (5 µm, 250 × 4.6 mm²; COSMOSIL) at 50 °C. Holo-VinP1 ACP₃CDD₃ was detected at 280 nm and eluted with a gradient of solvents B (0.1% TFA in water) and C (0.1% TFA in acetonitrile) at a flow rate of 1.5 mL/min (0–5 min 43% C, 5–25 min 43–53% C with a linear gradient, and 25–30 min 90% C) as a peak of retention time 16 min. The initial velocity of the transacylation between VinP2 NDD₄KS₄ and tiglyl-VinP1 ACP₃CDD₃ was calculated based on the HPLC peak area (Figure S6). Analyses of the transacylation between VinP2 NDD₄KS₄ and the other acyl-ACPCDD proteins were performed in the almost same manner except for the reaction time and the concentration of solvent C used in the HPLC analysis (Table S6).

Crosslinking reaction with α-haloacyl pantetheinamides: Br-Acetyl pantetheinamide and Cl-acetyl pantetheinamide were synthesized as described previously.^[20] For the VinP2 NDD₄KS₄AT₄ S684G-*crypto*-ACP₃CDD₃ crosslinking reaction, *crypto*-ACP₃CDD₃ was prepared. A total of 600 µM of each α-haloacyl pantetheinamide was mixed with 5 mM ATP, 5 mM MgCl₂, 2 µM CoaA, 2.8 µM CoaD, 2.4 µM CoaE, 20 µM Sfp and 400 µM of apo-ACP₃CDD₃ protein in buffer A. This modified reaction was carried out at 28 °C for 3 h, and this reaction mixture was directly used for the crosslinking reaction. For the crosslinking reaction, 50 µM of VinP2 NDD₄KS₄AT₄ S684G (or VinP2 NDD₄KS₄AT₄ C206G/S684G) was mixed with 200 µM of *crypto*-ACP₃CDD₃, which was then incubated at 20 °C. At 15, 120 and 360 min, samples of the crosslinking reaction mixture were taken, and the reaction was quenched by the addition of an equal volume of SDS-PAGE loading buffer [1% (v/v) 2-mercaptoethanol, 20% (v/v) glycerol, 1% (w/w) sodium dodecyl sulfate, and 50 mM Tris-HCl

(pH 6.8)] and the samples were analyzed by SDS-PAGE. For the crosslinking reaction between the VinP2 NDD₄KS₄AT₄ S684G and Cl-acetyl pantetheinamide-ACP(CDD) proteins, 200 μM of Cl-acetyl pantetheinamide-ACP(CDD) protein that was prepared in the same manner as *crypto*-ACP₃CDD₃ was mixed with 50 μM of VinP2 NDD₄KS₄AT₄ S684G. After incubation at 20 °C for 15 h, samples of the crosslinking reaction mixture were taken, and the reaction was quenched by the addition of an equal volume of SDS-PAGE loading buffer. The amount of the crosslinked complex was calculated using a Gel Doc EZ Imager (software; Image Lab 4.0, BIO RAD).

Acknowledgements

This work was supported in part by Grants-in-Aid for Scientific Research (B) (20H02911 to A.M.) and Grants-in-Aid for JSPS Fellows (20J13080 to T.C.) from the Japan Society for the Promotion of Science, and Grants-in-Aid for Scientific Research on Innovative Areas (16H06451 to T.E.) from the Ministry of Education, Culture, Sports, Science, and Technology (MEXT).

Conflict of Interest

The authors declare no conflict of interest.

Data Availability Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Keywords: acyl carrier protein · biosynthesis · ketosynthases · polyketide synthases · protein-protein interactions

- [1] C. T. Walsh, *Science* **2004**, *303*, 1805–1810.
- [2] A. T. Keatinge-Clay, *Nat. Prod. Rep.* **2012**, *29*, 1050–1073.
- [3] H. G. Smith, M. J. Beech, J. R. Lewandowski, G. L. Challis, M. Jenner, *J. Ind. Microbiol. Biotechnol.* **2021**, *48*, kuab018.
- [4] R. S. Gokhale, S. Y. Tsuji, D. E. Cane, C. Khosla, *Science* **1999**, *284*, 482–485.
- [5] S. Y. Tsuji, D. E. Cane, C. Khosla, *Biochemistry* **2001**, *40*, 2326–2331.
- [6] R. W. Broadhurst, D. Nietlispach, M. P. Wheatcroft, P. F. Leadlay, K. J. Weissman, *Chem. Biol.* **2003**, *10*, 723–731.
- [7] T. J. Buchholz, T. W. Geders, F. E. Bartley III, K. A. Reynolds, J. L. Smith, D. H. Sherman, *ACS Chem. Biol.* **2009**, *4*, 41–52.
- [8] N. Wu, S. Y. Tsuji, D. E. Cane, C. Khosla, *J. Am. Chem. Soc.* **2001**, *123*, 6465–6474.
- [9] N. Wu, D. E. Cane, C. Khosla, *Biochemistry* **2002**, *41*, 5056–5066.
- [10] Y. Ogasawara, K. Katayama, A. Minami, M. Otsuka, T. Eguchi, K. Kakinuma, *Chem. Biol.* **2004**, *11*, 79–86.
- [11] C. Y. Kim, V. Y. Alekseyev, A. Y. Chen, Y. Tang, D. E. Cane, C. Khosla, *Biochemistry* **2004**, *43*, 13892–13898.
- [12] T. Chisuga, A. Nagai, A. Miyanaga, E. Goto, K. Kishikawa, F. Kudo, T. Eguchi, *ACS Chem. Biol.* **2022**, *17*, 198–206.
- [13] L. E. N. Quadri, P. H. Weinreb, M. Lei, M. M. Nakano, P. Zuber, C. T. Walsh, *Biochemistry* **1998**, *37*, 1585–1595.
- [14] T. Robbins, J. Kapilivsky, D. E. Cane, C. Khosla, *Biochemistry* **2016**, *55*, 4476–4484.
- [15] S. Kapur, B. Lowry, S. Yuzawa, S. Kenthirapalan, A. Y. Chen, D. E. Cane, C. Khosla, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 4110–4115.
- [16] D. P. Cogan, K. Zhang, X. Li, S. Li, G. D. Pintilie, S.-H. Roh, C. S. Craik, W. Chi, C. Khosla, *Science* **2021**, *374*, 729–734.
- [17] J. C. Milligan, D. J. Lee, D. R. Jackson, A. J. Schaub, J. Beld, J. F. Barajas, J. J. Hale, R. Luo, M. D. Burkart, S. C. Tsai, *Nat. Chem. Biol.* **2019**, *15*, 669–671.
- [18] J. T. Mindrebo, A. Patel, W. E. Kim, T. D. Davis, A. Chen, T. G. Bartholow, J. J. La Clair, J. A. McCammon, J. P. Noel, M. D. Burkart, *Nat. Commun.* **2020**, *11*, 1–15.
- [19] C. Nguyen, R. W. Haushalter, D. J. Lee, P. R. L. Markwick, J. Bruegger, G. Caldara-Festin, K. Finzel, D. R. Jackson, F. Ishikawa, B. O'Dowd, J. A. McCammon, S. J. Opella, S. C. Tsai, M. D. Burkart, *Nature* **2014**, *505*, 427–431.
- [20] A. Miyanaga, R. Ouchi, F. Ishikawa, E. Goto, G. Tanabe, F. Kudo, T. Eguchi, *J. Am. Chem. Soc.* **2018**, *140*, 7970–7978.
- [21] D. Du, Y. Katsuyama, M. Horiuchi, S. Fushinobu, A. Chen, T. D. Davis, M. D. Burkart, Y. Ohnishi, *Nat. Chem. Biol.* **2020**, *16*, 776–782.
- [22] A. Miyanaga, S. Iwasawa, Y. Shinohara, F. Kudo, T. Eguchi, *Proc. Natl. Acad. Sci. USA* **2016**, *113*, 1802–1807.
- [23] S. Kapur, A. Worthington, Y. Tang, D. E. Cane, M. D. Burkart, C. Khosla, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3034–3038.
- [24] A. Miyanaga, S. Kurihara, T. Chisuga, F. Kudo, T. Eguchi, *ACS Chem. Biol.* **2020**, *15*, 1808–1812.
- [25] K. Finzel, D. J. Lee, M. D. Burkart, *ChemBioChem* **2015**, *16*, 528–547.
- [26] A. M. Gulick, C. C. Aldrich, *Nat. Prod. Rep.* **2018**, *35*, 1156–1184.
- [27] R. W. Haushalter, A. S. Worthington, G. H. Hur, M. D. Burkart, *Bioorg. Med. Chem. Lett.* **2008**, *18*, 3039–3042.
- [28] A. Miyanaga, R. Ouchi, F. Kudo, T. Eguchi, *Acta Crystallogr. Sect. F* **2021**, *77*, 294–302.
- [29] J. R. Whicher, S. S. Smaga, D. A. Hansen, W. C. Brown, W. H. Gerwick, D. H. Sherman, J. L. Smith, *Chem. Biol.* **2013**, *20*, 1340–1351.
- [30] S. Dutta, J. R. Whicher, D. A. Hansen, W. A. Hale, J. A. Chemler, G. R. Congdon, A. R. H. Narayan, K. Håkansson, D. H. Sherman, J. L. Smith, G. Skiniotis, *Nature* **2014**, *510*, 512–517.
- [31] S. Kapur, A. Y. Chen, D. E. Cane, C. Khosla, *Proc. Natl. Acad. Sci. USA* **2010**, *107*, 22066–22071.

Manuscript received: April 8, 2022
Revised manuscript received: April 29, 2022
Accepted manuscript online: May 2, 2022
Version of record online: May 16, 2022